Engrail Precision Neuroscience

Engrail Therapeutics is a clinical-stage pharmaceutical company dedicated to developing transformative therapies for diseases of the central nervous system. The company employs a precision neuroscience approach, utilizing deep insights into neurobiology to match specific mechanisms of action with defined patient populations. Their lead asset, ENX-102, is a subtype-selective GABA-A receptor positive allosteric modulator currently in Phase 2 development for generalized anxiety disorder. This molecule is designed to provide robust efficacy while minimizing the side effects typically associated with non-selective benzodiazepines. Engrail's pipeline also includes programs targeting dopamine receptors and other novel CNS pathways to address significant unmet needs in psychiatry and neurology.